Breaking News

Kinnate Biopharma Sells Investigational Pan-RAF Inhibitor to Pierre Fabre Laboratories

Pierre Fabre has purchased exarafenib and other pan-RAF assets and will assume 100% of the ongoing program and costs associated with these assets.

Kinnate Biopharma Inc., a clinical-stage precision oncology company, has agreed to sell its investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets to Pierre Fabre Médicament, SAS, a global player in oncology.
 
The sale of global rights is in furtherance of the Kinnate’s previously announced exploration of strategic alternatives.
 
“We are delighted to partner with Pierre Fabre Laboratories, a company that brings significant expertise in the global development and commercialization of targeted therapies in RAF and RAS driven solid tumors,” said Nima Farzan, Chief Executive Officer of Kinnate.  “The sale of exarafenib and our pan-RAF program assets to Pierre Fabre will expand the reach of these programs globally, allowing the promise of targeted therapies for patients with NRAS driven melanoma and BRAF driven solid tumors to further develop.”
 
“Based on the clinical and preclinical data generated to date, we believe exarafenib may present a best-in-class product profile as a pan-RAF inhibitor targeting solid tumors such as NRAS mutant melanoma, for which there are currently no approved targeted therapies. The addition of exarafenib and other pan-RAF program assets from Kinnate is complementary to our existing BRAF and MEK inhibitors portfolio with encorafenib and binimetinib. This acquisition continues to expand our efforts in precision oncology and provide us with the opportunity to broaden our reach to patients in need for targeted therapies in RAF and RAS solid tumors,” added Francesco Hofmann, Head of Research and Development for Medical Care at Pierre Fabre Laboratories.

Terms of the Agreement

Under the terms of the APA, Pierre Fabre Laboratories has purchased exarafenib and other pan-RAF assets and will assume 100% of the ongoing program and costs associated with these assets. In consideration, Kinnate will receive a total consideration of up to $31 million, consisting of $500,000 at closing, and a $30.5 million payment, contingent upon the earlier of the dosing of the first patient in the first pivotal trial for exarafenib or any other acquired asset, or the application for an accelerated approval pursuant to the FDA’s Accelerated Approval Program for exarafenib or any other acquired asset, or the submission of a marketing application for regulatory approval for exarafenib or any other acquired asset.
 
In addition, Pierre Fabre Laboratories will assume up to $5 million of trade payables for the transferred assets. The transaction is not subject to closing conditions and closed upon signing.
 
This news comes months after Pierre Fabre Laboratories acquired Vertical Bio AG, a developer of novel cancer therapies.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters